secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tvardi Therapeutics, Inc. (TVRD)
CIK:        0001346830
Form:       8-K
Filed at:   2025-04-11T23:59:59+00:00
Accession:  0001104659-25-034220
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cara Therapeutics issues investor deck for pending merger with Tvardi (STAT3 fibrosis program)
--------------------------------------------------------------------------------

- Merger with Tvardi Therapeutics (STAT3 inhibitor developer for fibrosis) announced Dec 17, 2024; closing conditions remain.
- Investor presentation shared with potential investors outlines Tvardi's clinical pipeline and post-combination strategy.
- No new financial terms disclosed; forward-looking statements caution on risks related to closing timing and regulatory submissions.
- Tvardi focuses on oral small-molecule STAT3 therapies for fibrosis-driven diseases with significant unmet need.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1346830/000110465925034220/0001104659-25-034220-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1346830/000110465925034220/tm2512145d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-034220

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer